Centre For Clinical Research And Biostatistics (CCRB)

Back

1 Unique Trial Number (assigned by CCRB)

CUHK_CCT00021

2 Trial Registration Date

2005-09-08

iRegistration Status

Retrospective

3 Secondary IDs

4 Source(s) of Funding

Schwarz Pharma (HK) Ltd

5 Primary Sponsor

Schwarz Pharma (HK) Ltd

6 Secondary Sponsor

Function

Please specify

7Responsible Contact Person (public contact person for patients interested in participating)

i Name

Benny Fok

ii Address

iii Phone

bfok@cuhk.edu.hk

iv Email

email

v Affiliation

vi Country

8Research Contact Person (person to contact for scientific inquiries)

i Name

Brian Tomlinson

ii Address

iii Phone

btomlinson@cuhk.edu.hk

iv Email

email

v Affiliation

vi Country

9 Official Scientific Title of the Study

Comparison of lercanidipine with felodipine in essential hypertension including subjects with isolated systolic hypertension

10 Public Title

i Public Title in Chinese 研究名稱

11 Short Title (Optional)

12 Countries of Recruitment

13Research Ethic Review

i Has the study received appropriate ethics approval?

Yes

ii When is the approval date?

2001-07-11

iii Full Name of IRB/IEC

Please specify

iv IRB/IEC approval reference number

14 Medical Condition Being Studied

Heart and Blood Vessel Diseases

15Intervention

i Types of intervention

Drug

Please specify

ii Description/ name of Intervention/article

Lercanidipine

iii Dosage form of the intervention

iv Dosage of the intervention

v Duration of the intervention

16 weeks

vi Frequency of the intervention

16Comparative Treatments

i Description/ name of comparative treatments

Felodipine

ii Dosage form of the comparative treatments

iii Dosage of the comparative treatments

iv Duration of the comparative treatments

v Frequency of the comparative treatments

17Key Inclusion and Exclusion Criteria

i Inclusion Criteria

Adult patients with mild to moderate essential hypertension

ii Exclusion Criteria

iii Age Minimum

iv Age Maximum

v Gender

18 Study Type

19Study Design

i Randomization

Randomized

Please specify

ii Nature of control

Active

iii Degree of masking

Double-blind

If Single-blind, who will be masked?

iv Group Assignment

Parallel

v Study Phase

Please specify

vi Study Objectives (Optional)

20 Anticipated trial start date

2001-11-01

21 Target Sample Size

30

22 Recruitment Status

Complete

23 Primary Outcome

Changes in blood pressure

24 Secondary Outcome

renal function, markers of oxidative stress, inflammation and endothelial function

25Study Information/Publication

i Study Information/Publication Available?

No

ii Link to Study Information/Publication

26Last Update Date

2005-09-08

27 Primary Registry and Trial Identifying Number

28 Date of Registration in Primary Registry

* Legacy Fields

i Recruitment Information Available?

Yes

ii Link to Recruitment Information

None

Back

Trial History Detail on 2005-09-08